List view / Grid view
In November 2012, the US Food and Drug Administration accepted…
In November 2012, the US Food and Drug Administration accepted the use of the MycoTOOL® PCR Mycoplasma Detection Kit as a release method for a biopharmaceutical product manufactured by Roche Applied Science intended for distribution in the United States.
The National Institutes of Health Center for Regenerative Medicine (NIH…
The National Institutes of Health Center for Regenerative Medicine (NIH CRM) has awarded Lonza Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) under current Good Manufacturing Practices (cGMP). The production of clinical grade iPSCs is considered a critical component to realizing the therapeutic potential of pluripotent stem…
Lonza has entered a worldwide, non-exclusive licensing agreement with iPS…
Lonza has entered a worldwide, non-exclusive licensing agreement with iPS Academia Japan, Inc. for its induced pluripotent stem cell (iPSC) patent portfolio. By entering this agreement, Lonza demonstrates its commitment to the field of regenerative medicine and reinforces its belief that iPSCs are a key platform technology for the cell…
Lonza (SIX Swiss Exchange: LONN) and Roche (SWX: ROG) announced…
Lonza (SIX Swiss Exchange: LONN) and Roche (SWX: ROG) announced today that they have entered into a co-exclusive distribution agreement for the commercialization of Roche’s MycoTOOL® mycoplasma Polymerase Chain Reaction (PCR) assays.
